BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34309658)

  • 1. Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.
    Sedano R; Hogan M; Nguyen TM; Chang J; Zou GY; Macdonald JK; Vande Casteele N; Hanzel J; Crowley E; Battat R; Dulai PS; Singh S; D'Haens G; Sandborn W; Feagan BG; Ma C; Jairath V
    J Crohns Colitis; 2022 Feb; 16(2):224-243. PubMed ID: 34309658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.
    Jairath V; Zou GY; Parker CE; MacDonald JK; AlAmeel T; Al Beshir M; Almadi MA; Al-Taweel T; Atkinson NS; Biswas S; Chapman T; Dulai PS; Glaire MA; Hoekman DR; Koutsoumpas A; Minas E; Mosli MH; Samaan M; Khanna R; Travis S; D'Haens G; Sandborn WJ; Feagan BG
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011572. PubMed ID: 28886205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.
    Jairath V; Zou G; Parker CE; Macdonald JK; Mosli MH; Khanna R; Shackelton LM; Vandervoort MK; AlAmeel T; Al Beshir M; AlMadi M; Al-Taweel T; Atkinson NS; Biswas S; Chapman TP; Dulai PS; Glaire MA; Hoekman D; Koutsoumpas A; Minas E; Samaan MA; Travis S; D'Haens G; Levesque BG; Sandborn WJ; Feagan BG
    J Crohns Colitis; 2016 May; 10(5):607-18. PubMed ID: 26746169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological Remission Placebo Rates in Ulcerative Colitis Trials: A Systematic Review and Meta-analysis.
    Youssef M; Dong K; Lee SJ; Narula N
    Inflamm Bowel Dis; 2024 Jan; 30(1):125-131. PubMed ID: 36753516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis.
    Ma C; Guizzetti L; Panaccione R; Fedorak RN; Pai RK; Parker CE; Nguyen TM; Khanna R; Vande Casteele N; D'Haens G; Sandborn WJ; Feagan BG; Jairath V
    Aliment Pharmacol Ther; 2018 Jun; 47(12):1578-1596. PubMed ID: 29696670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vedolizumab for induction and maintenance of remission in ulcerative colitis.
    Bickston SJ; Behm BW; Tsoulis DJ; Cheng J; MacDonald JK; Khanna R; Feagan BG
    Cochrane Database Syst Rev; 2014 Aug; (8):CD007571. PubMed ID: 25105240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral budesonide for induction of remission in ulcerative colitis.
    Sherlock ME; MacDonald JK; Griffiths AM; Steinhart AH; Seow CH
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD007698. PubMed ID: 26497719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, Endoscopic, and Safety Placebo Rates in Induction and Maintenance Trials of Crohn's Disease: Meta-Analysis of Randomised Controlled Trials.
    Almradi A; Sedano R; Hogan M; Zou GY; MacDonald JK; Parker CE; Hanzel J; Crowley E; Singh S; D'Haens G; Sandborn WJ; Feagan BG; Ma C; Jairath V
    J Crohns Colitis; 2022 Jun; 16(5):717-736. PubMed ID: 34758084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Battat R; Duijvestein M; Guizzetti L; Choudhary D; Boland BS; Dulai PS; Parker CE; Nguyen TM; Singh S; Vande Casteele N; Pai RK; Feagan BG; Sandborn WJ; Jairath V
    Am J Gastroenterol; 2019 May; 114(5):733-745. PubMed ID: 30694863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate for maintenance of remission in ulcerative colitis.
    Wang Y; MacDonald JK; Vandermeer B; Griffiths AM; El-Matary W
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD007560. PubMed ID: 26263042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methotrexate for induction of remission in ulcerative colitis.
    Chande N; Wang Y; MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD006618. PubMed ID: 25162749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
    Rubin DT; Dotan I; DuVall A; Bouhnik Y; Radford-Smith G; Higgins PDR; Mishkin DS; Arrisi P; Scalori A; Oh YS; Tole S; Chai A; Chamberlain-James K; Lacey S; McBride J; Panés J;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):17-27. PubMed ID: 34798036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Marshall JK; Thabane M; Steinhart AH; Newman JR; Anand A; Irvine EJ
    Cochrane Database Syst Rev; 2012 Nov; 11():CD004118. PubMed ID: 23152224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease.
    Jairath V; Zou G; Parker CE; MacDonald JK; Mosli MH; AlAmeel T; Al Beshir M; AlMadi M; Al-Taweel T; Atkinson NS; Biswas S; Chapman TP; Dulai PS; Glaire MA; Hoekman D; Kherad O; Koutsoumpas A; Minas E; Restellini S; Samaan MA; Khanna R; Levesque BG; D'Haens G; Sandborn WJ; Feagan BG
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1021-1042. PubMed ID: 28164348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endoscopic and Histological Placebo Rates in Crohn's Disease Clinical Trials: A Systematic Review and Meta-analysis.
    Vuyyuru SK; Nguyen TM; Hogan M; Raine T; Noor NM; Narula N; Verstockt B; Feagan BG; Singh S; Ma C; Jairath V
    Inflamm Bowel Dis; 2024 Apr; 30(4):651-659. PubMed ID: 37002875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etrolizumab for induction of remission in ulcerative colitis.
    Rosenfeld G; Parker CE; MacDonald JK; Bressler B
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011661. PubMed ID: 26630451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.